Neuron Biopharma, S.A. filed its Annual on Apr 30, 2013 for the period ending Dec 31, 2012. In this report its auditor, Deloitte & Touche LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% | -.--% | -.--% |
2017 | Neuron BioLabs, S.L. cancelled the acquisition of diagnostics operations, R&D services and patents of Alzheimer's disease from Neuron Bio, SA. | CI |
2017 | Neol Biosolutions Seeks Investors | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 5.19M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- NEU Stock
- News Neuron Bio, S.A.
- Neuron Biopharma, S.A. Auditor Raises 'Going Concern' Doubt